Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214688 · ClinicalTrials.gov registry record · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
A Phase 2 study of Allogeneic Stem Cell Transplant Recipient, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
- 3
- Study locations
NCT07214688: Recruiting Phase 2 study of Allogeneic Stem Cell Transplant Recipient, sponsored by Hackensack Meridian Health.
NCT07214688 is a Phase 2 study of Allogeneic Stem Cell Transplant Recipient that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 209 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (57% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214688, a Phase 2 study of Allogeneic Stem Cell Transplant Recipient, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
- 3
- Study locations
Study Summary
The Flu-TBI 800 trial is a prospective, single-arm, multicenter, interventional phase 2 study to evaluate whether fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy) (experimental regimen) improves the 1-year survival of allogeneic stem cell transplant recipients.
Primary Outcome
OS is defined as the time from the first dose of study treatment to the time of death due to any cause. Patients who are still alive will be censored at the date last known alive of the data cut-off date (if applicable), whichever is earlier.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil (MMF)
- RADIATION Intermediate-dose Total Body Irradiation (TBI)
- DRUG Post-transplant Cyclophosphamide (PTCy)
Study Locations (3)
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
- John Theurer Cancer Center at Jersey Shore University Medical Center - Neptune City
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2026-01-06 |
| Est. Completion | 2032-01 |
| Phase | Phase 2 |
What NCT07214688 shows while recruiting
NCT07214688 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Allogeneic Stem Cell Transplant Recipient appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT07214688 reports a single indexed study location in New Jersey, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT07214688 about?
NCT07214688 is a clinical study titled "Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies". The Flu-TBI 800 trial is a prospective, single-arm, multicenter, interventional phase 2 study to evaluate whether fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy) (experimental regimen) improves the 1-year survival of allogeneic ste...
What is the current status of trial NCT07214688?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2026-01-06. Estimated completion is 2032-01.
What conditions does trial NCT07214688 study?
This clinical trial studies the following conditions: Allogeneic Stem Cell Transplant Recipient.
What interventions are being tested in trial NCT07214688?
The interventions under investigation include: Fludarabine (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (MMF) (DRUG), Intermediate-dose Total Body Irradiation (TBI) (RADIATION), Post-transplant Cyclophosphamide (PTCy) (DRUG).
Who is sponsoring clinical trial NCT07214688?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214688 being conducted?
This trial has 3 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Stem Cell Transplant Recipient
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07214688's enrollment target sits among peer trials
209 294th of 2000 higher than 1,707 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI